CTI BioPharma Announces Data Presentations at the 57th ASH Annual Meeting

CTI BioPharma Corp. CTIC today announced that data highlighting two compounds (pacritinib and tosedostat) from the company's investigational pipeline will be presented at the upcoming 57th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 5-8 in Orlando, FL – including three oral presentations. The presentations will include data analyses from the Phase 3 PERSIST-1 trial of pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R that is currently under investigation for the treatment of patients with myelofibrosis and acute myeloid leukemia (AML) as well as findings from a Phase 2 study of tosedostat, an investigational oral selective inhibitor of aminopeptidases that has demonstrated anti-tumor responses in blood-related cancers and solid tumors in Phase 1-2 clinical trials. "We look forward to the presentation of data for both pacritinib and tosedostat at this year's ASH annual meeting," said James A. Bianco, M.D., President and CEO of CTI BioPharma. "With six abstracts accepted, the data involving two of our investigational compounds is a further example of our focused commitment on advancing the development of our pipeline candidates." A summary of the oral and poster presentations See full press release